Clinical Trials 101 | Alzheimer's Prevention Registry

You are here

Clinical Trials 101

2018—A Year in Research

Once again, it’s time to reflect on the preceding 12 months. Despite the 2025 deadline for effective therapy that has been set by the National Alzheimer’s Plan and the World Dementia Council, 2018 brought no drug approvals or Phase 3 breakthroughs. Short of that, however, smaller advances happened across neurodegenerative research this past year. 

National Recruitment Strategy Aims to Open Doors Wider to Participation in Research Studies

You may have heard of the ambitious goal set by the U.S. National Plan to Address Alzheimer’s Disease – to prevent and effectively treat Alzheimer’s disease by 2025. While this plan offers great promise, it also shines the spotlight on the need for volunteer research participants. 

Alzheimer's Stigma Hinders Research

Currently, several trials are trying to develop therapies for AD by 2025. These trials’ success, however, depends upon participants who are willing to undergo genetic and biomarker testing to learn if they are at risk of AD dementia. 

Blood Test Could Predict the Risk of Alzheimer's

Researchers hope the test will help with drug trials and early intervention

Inside One Couple’s Experimental Treatment to Battle Alzheimer’s Disease

Married for more than 50 years, the Woodings are among the more than 5 million Americans who are facing Alzheimer’s disease, one of the most devastating diagnoses today. But instead of accepting the slow descent into memory loss, confusion and dementia, Peter–who has the disease–could be among the first to successfully stop that decline from happening.

Merck Will End Alzheimer's Trial as Alternative Approach Fails

Merck & Co. will stop its final-stage test of an Alzheimer’s compound that was once seen as a promising alternative to other now-failed approaches.Merck & Co. will stop its final-stage test of an Alzheimer’s compound that was once seen as a promising alternative to other now-failed approaches.

Exercise may not be the silver bullet – but it’s still important

Exercise – or moving your body for those who don’t like the “e-word” – is good for us. Upon that fact, there’s widespread agreement. There also have been proven positive correlations between physical activity and cognitive health. So a natural question is, can you do an “exercise intervention” – starting exercise early in life in an effort to ensure cognitive health in your later years?

Pfizer Halts Research Into Alzheimer's And Parkinson's Treatments

Pfizer has announced plans to end its research efforts to discover new drugs for Alzheimer's and Parkinson's diseases.

Alzheimer's Biomarkers, Explained

Developing new biomarkers is a priority for the Alzheimer’s Drug Discovery Foundation (ADDF). These tools are critical to the success of our mission to find effective ways to prevent and treat Alzheimer’s disease and other types of dementia.

2017 – A Year of Trials and Tribulations in Alzheimer’s Research

As the year 2017 rolled in, hopes were high that a few clinical trials would have a positive outcome, resulting in a possible new treatment for Alzheimer’s disease.  Although there weren’t any major breakthroughs, the fact is that we learn from our research no matter what the outcome. And that was certainly the case this year.